Active Recombinant Mouse Cd83 Protein, Fc Chimera

• Cat.No.: Cd83-625M
• Product Overview: Recombinant Mouse Cd83 (Accession # NP_033986), fused with , was produced in Spodoptera frugiperda, Sf 21 (stably transfected)-derived.

Specification

• Source: Sf21 Insect Cells
• Species: Mouse
• Tag: Fc
• Predicted N Terminal: Met22
• Form: Lyophilized from a 0.2 µm filtered solution in PBS.
• Bio-activity: Measured by the ability of the immobilized protein to support the adhesion of human monocyte-derived dendritic cells.When 5 x 10^4 cells/well are added to mouse CD83/Fc coated plates (2.5 µg/mL with 100 µL/well), approximately 50 - 75% will adhere after 1 hour incubation at room temperature. Optimal dilutions should be determined by each laboratory for each application.
• Molecular Mass: Recombinant Mouse Cd83, Fc Chimera has a calculated MW of 39.1 kDa (monomer). In SDS-PAGE migrates as 52 kDa, reducing conditions.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Storage: Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).

Gene Information

• Gene Name: Cd83 CD83 antigen [ Mus musculus ]
• Official Symbol: Cd83
• Synonyms: CD83; CD83 antigen; mCD83; MGC130312; MGC130313
• Gene ID: 12522
• mRNA Refseq: NM_009856
• Protein Refseq: NP_033986

Reviews

03/16/2021

The experimental conditions are wide, and the experimental results are accurate and reproducible.

08/24/2020

The resulting strips are clear and bright, which greatly exceeds the expected results.

06/10/2020

CD83 activity is maintained for a very long time and can be maintained for a long time, which is very stable and reliable.

Q&As

Could CD83 be a target for immunotherapy?

Yes, CD83 can be targeted as immunotherapy. Immunotherapy for CD83 has been explored in several clinical trials with some efficacy.

Are there population differences in CD83 treatment?

It is unclear whether there is a population difference in CD83 treatment. However, due to factors such as individual differences and genetic polymorphisms, different populations may respond differently to treatment. Therefore, population-specific treatment strategies may need to be individually adapted and optimized.

What are possible aspects of future research on CD83?

Future research on CD83 may involve more in-depth molecular mechanism studies, optimization and improvement of CD83-based immunotherapy strategies, and research on combination with other immunotherapies or drugs.

Is there a relationship between CD83 and other immune checkpoint molecules?

CD83 interacts and regulates with other immune checkpoint molecules. Together, they are involved in the regulation of the immune response.

Is CD83 expression regulated by other molecules?

Yes, CD83 expression is regulated by a variety of molecules, including cytokines, transcription factors, and epigenetic modifications.

What is the therapeutic approach for CD83?

Current treatments for CD83 mainly include immunotherapy and gene therapy. Immunotherapy against CD83 works primarily by modulating the function of dendritic cells and T cells.